Compare StocksABBV vs REGN

AbbVie Inc. (ABBV) vs Regeneron Pharmaceuticals, Inc. (REGN): Which Is the Better Buy in 2026?

As of 2026-08-03, ABBV is overvalued at $246, with a DCF intrinsic value of $178 and a margin of safety of -38%. REGN is undervalued at $764, with an intrinsic value of $1362 and a margin of safety of 44%. Of the two, REGN has the wider margin of safety.

ABBV
AbbVie Inc.
$246.19
VS
REGN
Regeneron Pharmaceuticals, Inc.
$763.62

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
REGN
  • Regeneron Pharmaceuticals, Inc. scores 80/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
  • Altman Z-Score of 7.56 indicates very low bankruptcy risk — the company is firmly in the safe zone.
  • Net debt/EBITDA of -1.1x means the company holds more cash than debt — a net cash position.

Risks

ABBV
  • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • Free cash flow has declined at a 9.8% CAGR over the past 4 years — a concerning trend.
REGN
  • ROIC has declined by 7.3 percentage points over the past 4 years, which may signal competitive erosion.
  • Each dollar of retained earnings has produced only $0.15 of earning power — shareholders may have been better served by dividends.
  • 11 insider sales with no purchases over the past 12 months — a persistent pattern of insider selling.

Key Valuation Metrics

Learn more →
ABBV
REGN
Valuation
N/A
Free Cash Flow
$3.07B
N/A
FCF Yield
3.90%
69.55
Trailing P/E
18.89
15.12
Forward P/E
12.80
Quality & Moat
27.60%
ROIC
11.80%
N/A
ROE
14.04%
72.79%
Gross Margin
44.46%
0.41
PEG Ratio
1.34
Balance Sheet Safety
N/A
Net Debt / Equity
Net cash
N/A
Interest Coverage
N/A
2.06
Net Debt / EBITDA
-1.12
2.76%
Dividend Yield
0.49%
ABBV: 4Ties: 1REGN: 3
ABBVREGN

Historical Fundamentals

Learn more →
ABBV

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

REGN

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
REGN
$0.20
created per $1 retained over 3 years
Value Destroyer
Σ Retained
$12.50B
Δ Market Cap
+$2.52B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ABBV
38.1% Overvalued
Price is 38.1% above estimated fair value
Current Price: $246.19
Fair Value: $178.31
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
REGN
44.0% Margin of Safety
Price is 44.0% below estimated fair value
Current Price: $763.62
Fair Value: $1362.39
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ABBV

Requires positive FCF to compute implied growth rate.

REGN

What growth rate is the market pricing in at $764?

+4.9%
Market-Implied Owner Earnings Growth
Standard FCF implies +10.1%

The market implies +4.9% Owner Earnings growth, roughly in line with history — reasonably priced.

Standard FCF implies +10.1%, reflecting ongoing growth investment.

Economic Moat Score

Learn more →
ABBV
82/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
REGN
80/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

Forensic Accounting

Learn more →
ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
REGN
-2.51
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ABBV
Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
No. of Institutional Holders5,146
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
REGN
Insiders 2.1%Institutions 93.7%Retail & Other 4.2%
No. of Institutional Holders1,936
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
REGN
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ABBV
0
Sells (3M)
0
Sells (12M)
No open market insider sales found.
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
REGN
1
Sells (3M)
11
Sells (12M)
Total value (12M): $9.60M
RYAN ARTHUR F.
Director
$130,030
@ $650.15 · 2026-07-02
RYAN ARTHUR F.
Director
$70,524
@ $705.24 · 2026-05-01
RYAN ARTHUR F.
Director
$77,727
@ $777.27 · 2026-04-01
RYAN ARTHUR F.
Director
$78,550
@ $785.50 · 2026-03-02
ZOGHBI HUDA Y
Director
$1.28M
@ $781.33 · 2026-02-19
RYAN ARTHUR F.
Director
$77,853
@ $778.53 · 2026-02-09
PITOFSKY JASON
Officer
$1.59M
@ $778.52 · 2026-02-09
BASSLER BONNIE L
Director
$1.20M
@ $800.00 · 2026-01-07
BASSLER BONNIE L
Director
$570,000
@ $750.00 · 2025-11-20
PITOFSKY JASON
Officer
$280,766
@ $651.43 · 2025-11-07
POON CHRISTINE A
Director
$4.25M
@ $654.27 · 2025-10-29
MCCOURT MARION E
Officer
$844,610
@ $844.61 · 2024-11-01
MCCOURT MARION E
Officer
$1.05M
@ $1054.06 · 2024-10-01
RYAN ARTHUR F.
Director
$104,878
@ $1048.78 · 2024-10-01
MCCOURT MARION E
Officer
$1.18M
@ $1178.73 · 2024-09-03
RYAN ARTHUR F.
Director
$117,868
@ $1178.68 · 2024-09-03
POON CHRISTINE A
Director
$12.55M
@ $1158.17 · 2024-08-15
BASSLER BONNIE L
Director
$884,520
@ $1170.00 · 2024-08-15
MURPHY ANDREW J
Officer
$7.34M
@ $1153.15 · 2024-08-14
STAHL NEIL E
Officer
$5.64M
@ $1084.54 · 2024-08-08
PITOFSKY JASON
Officer
$521,090
@ $1070.00 · 2024-08-07
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ABBV
FearGreed
😐Neutral(59/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
REGN
FearGreed
😏Greed(67/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ABBV
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (59)
REGN
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (67)
View ABBV Full AnalysisView REGN Full Analysis

Frequently Asked Questions: ABBV vs REGN

Is AbbVie Inc. or Regeneron Pharmaceuticals, Inc. more undervalued in 2026?

Based on our discounted cash flow model, REGN trades at a 44.0% margin of safety (intrinsic value $1362 vs. price $764), compared to ABBV's -38.1% margin of safety (intrinsic $178 vs. $246).

Which stock has a wider economic moat, AbbVie Inc. or Regeneron Pharmaceuticals, Inc.?

ABBV scores 82/100 (Wide moat), while REGN scores 80/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is AbbVie Inc. in financial distress?

ABBV's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. REGN scores 7.6 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which stock has higher return on invested capital, AbbVie Inc. or Regeneron Pharmaceuticals, Inc.?

ABBV earns 27.6% ROIC versus REGN's 11.8%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, AbbVie Inc.'s or Regeneron Pharmaceuticals, Inc.'s?

REGN's dividend earns a safety score of 85/100 (Very Safe), compared to ABBV's 39/100 (Unsafe). REGN has raised its dividend for 0 consecutive years.